Status
Conditions
Treatments
About
This retrospective study will leverage previous immune function monitoring results in conjunction with clinical case data at this medical center.
Full description
The primary aim of this study is to evaluate the efficacy and safety of PD(L)-1 antibody therapy for malignant tumors in real-world settings. Treatment outcomes will be assessed according to RECIST V1.1 and iRECIST criteria, with safety graded according to CTCAE V5.0 standards. The study aims to enroll 3000 adult cancer patients treated at this center and analyze their prognosis outcomes based on previous treatment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
3,000 participants in 2 patient groups
Loading...
Central trial contact
Xiaomin Fu; Xiaomin Fu
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal